Financial policy issues for HIV pre-exposure prophylaxis: Cost and access to insurance

American Journal of Preventive Medicine

Volumn 44, Issue 1 SUPPL. 2, 2013, Pages

  Horberg, Michael ^a   Raymond, Brian ^b  

^a Mid Atlantic Permanente Research Institute   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; TENOFOVIR;

ARTICLE; CLINICAL PRACTICE; DRUG COST; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; LABORATORY; PREEXPOSURE PROPHYLAXIS;

EID: 84871755507     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2012.09.039     Document Type: Review

References (23)

1. U.S. Food and Drug Administration (FDA) FDA approves first drug for reducing the risk of sexually acquired HIV infection 2012 FDA Silver Spring MD
2. P. Hazelton Financing and delivery mechanisms to increase pre-exposure prophylaxis (PrEP) access in populations at high-risk of HIV infection, a paper prepared for the Advanced Policy Analysis for the Goldman School of Public Policy from the University of California, Berkeley 2011 University of California Berkeley CA
3. K.A. Gebo, J.A. Fleishman, R. Conviser Contemporary costs of HIV healthcare in the HAART era AIDS 24 17 2010 2705 2715
4. Meenan R, O'Keeffe Rosetti M, Kimes T, et al. Abstract TUPE0236; Excess prevalence-based costs of multiple HAART switches among HIV+ patients in a U.S. health maintenance organization. Proceedings of the XVII International AIDS Conference; 2008 Aug 3-8; Mexico City, Mexico.
5. K. Desai, S.L. Sansom, M.L. Ackers Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the U.S.: HIV infections prevented and cost-effectiveness AIDS 22 14 2008 1829 1839
6. A.D. Paltiel, K.A. Freedberg, C.A. Scott HIV preexposure prophylaxis in the U.S.: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness Clin Infect Dis 48 6 2009 806 815
7. CDC Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men MMWR Morb Mortal Wkly Rep 60 3 2011 65 68
8. The Body. Test Positive Aware Network. Cost of Truvada. 2011 www.thebody.com/content/art1331.html
9. Panel on Antiretroviral Guidelines for Adult and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2012 DHHS Washington DC 1 128
10. Center for Medicare & Medicaid Services (CMMS), DHHS CMS 2012 clinical diagnostic laboratory fee schedule 2012 CMMS Washington DC
11. CDC CDC HIV/AIDS facts, Q&A: CDC's clinical studies of pre-exposure prophylaxis for HIV prevention 2009 DHHS Atlanta GA
12. K. Underhill, D. Operario, M. Skeer, M. Mimiaga, K. Mayer Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice J Acquir Immune Defic Syndr 55 1 2010 8 13
13. AIDS Vaccine Advocacy Coalition (AVAC). Summary from the AVAC Think Tank on PrEP Financing in the U.S.; 2009 Jan 14; San Francisco CA.
14. A.Y. Liu, E. Vittinghoff, D.E. Sellmeyer Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco PLoS One 6 8 2011 e23688
15. Y. Yazdanpanah Costs associated with combination antiretroviral therapy in HIV-infected patients J Antimicrob Chemother 53 4 2004 558 561
16. The Henry J. Kaiser Family Foundation Kaiser Commission on Medicaid and the Uninsured: key facts 2011 The Henry J. Kaiser Family Foundation Washington DC
17. E.R. Boukus, E.R. Carrier Americans' access to prescription drugs stabilizes, 2007-2010 Track Rep 27 2011 1 5
18. G. Szekeres, T. Coates, S. Frost, A. Leibowitz, S. Shoptaw Anticipating the efficacy of HIV pre-exposure prophylaxis (PrEP) and the needs of at-risk Californians 2004 University of California Los Angeles Los Angeles CA
19. T.G. Heckman, A.M. Somlai, J. Peters Barriers to care among persons living with HIV/AIDS in urban and rural areas AIDS Care 10 3 1998 365 375
20. Gilead Sciences Inc. Truvada Medication Assistance Program 2012 www.gilead.com/truvada-assistance-program
21. M. Horberg PrEP: access and cost from private sector payor International Association of Physicians in AIDS Care, ed TasP PrEP Evidence Summit: controlling the HIV pandemic with antiretrovirals: treatment as prevention and pre-exposure prophylaxis 2012 London, UK
22. The White House Office of National AIDS Policy National HIV/AIDS strategy for the U.S. 2010 ONAP Washington DC
23. One Hundred Eleventh Congress of the U.S. The Patient Protection and Affordable Care Act U.S. 2010 1 906